Ovid Therapeutics Культура компании

Dr. Amit Rakhit, M.D., M.B.A., has been Chief Medical & Portfolio Management Officer at Ovid Therapeutics Inc. since March 2016. Dr. Rakhit leads Ovid's clinical efforts and oversees medical affairs and commercialization of Ovid Therapeutics's therapeutic portfolio. Dr. Rakhit serves as Member of Advisory Board at New York City Investment Fund Manager, Inc. and focuses on the health care sector. Dr. Rakhit served as Senior Vice President and Head of Worldwide Medical at Biogen, leading its global medical teams, with a focuses on commercial launch activities and pipeline support for disease areas including neurology, hematology and immunology. He also served as Vice President of Program Leadership & Management at Biogen, running global development and commercialization programs focused on orphan diseases and neurodegenerative disorders such as ALS and Spinal Muscular Atrophy. Previously, Dr. Rakhit held leadership roles at Bristol-Myers Squibb, including Director, Cardiovascular R&D, focused on Plavix???, and Executive Medical Director, Cardiovascular/Metabolics EMEA, in which role he oversaw European medical activities for Plavix???, Avapro ???, Pravachol???, Coumadin???, Onglyza???, and Eliquis???. Attaining the role of Vice President, Intercontinental Medical, he was ultimately responsible for business expansion and cross-portfolio R&D efforts across 27 markets. Dr. Rakhit received his B.A. degree in molecular cell biology from the University of California, Berkeley and his M.S. degree in clinical investigation from Vanderbilt University. He also received his M.D. degree from Tufts University School of Medicine and dual M.B.A. degrees from Columbia University School of Business and London Business School. Dr. Rakhit completed his fellowship training at Boston Children's Hospital affiliated with Harvard Medical School.

Dr. Dirk Haasner, Ph.D., MPM has been Senior Vice President of Global Regulatory Affairs & Manufacturing at Ovid Therapeutics Inc. since March 2016. Dr. Haasner serves as Head of Regulatory and Medical Affairs of USA at Lundbeck Pharmaceuticals Ltd. He served as Vice President of Global Regulatory Affairs at Ovid Therapeutics Inc. from December 2015 to March 2016. Dr. Haasner was Vice President of Regulatory and Medical Affairs and Vice President Regulatory Strategy and Policy at Lundbeck USA, Inc., from February 2002 to November 2015, with responsibility for all FDA interactions on several marketed orphan drugs and all Lundbeck development compounds. Dr. Haasner was co-founder of 4-Antibody AG and served as its Consultant. Since 2002, he has been Director of Pharma Marketing and Regulatory Affairs at Lundbeck Inc., where he was responsible for marketing Lundbeck's products in the US at a Lundbeck subsidiary in New York. He started an industry career in Pharma Project Management at Hoffmann-LaRoche, Basel, where he served as Vice Director and Global LifeCycle Leader for one of Roche's top selling products. From 1994 to 2002, Dr. Haasner was employed at F. Hoffmann-La Roche AG, where he held positions of increasing responsibility in global product development and global strategic marketing before being appointed Global Life-cycle Leader. Dr. Haasner is an expert in pharma marketing and regulatory affairs and was responsible for managing the interactions and communications with the Federal Drug Administration for Roche and he was also closely involved in the strategic development of the US market. Dr. Haasner obtained his PhD in Cell Biology and Immunology from the University of Basel for work on early B cell development done at the Basel Institute for Immunology and holds a postgraduate degree in Pharmaceutical Medicine from the EUCOR Universities Basel, Strasbourg and Freiburg. Dr. Haasner obtained a MSc in Molecular Biology at the University of Basel, Switzerland.

Dr. Yaron Werber, M.D., has been the Chief Financial Officer and Chief Business Officer of Ovid Therapeutics Inc. since June 22, 2015 and July 2016 respectively. Dr. Werber has been Secretary of Ovid Therapeutics Inc. since July 2015 and has been its Treasurer since April 2017. He serves as a Venture Advisor at Israel Biotech Fund. Dr. Werber served as Managing Director of Citigroup Inc., Research Division (Citi Research) and the Head of the Healthcare and Biotech Equity Research teams. During his 11-year tenure at Citi, Dr. Werber and his team have conducted in-depth analysis of more than 80 life science companies at all stages of development, ranging from successful profitable companies to recently public and privately held companies. He was employed at the Citigroup until May 2015 and led the biotechnology and small-cap specialty pharma research team at the Citigroup. He joined the Citigroup Inc., Research Division from Cowen and Company, LLC, Research Division where he was a Senior Analyst. Previously, he was a Consultant in the biomedical arena, a pharmaceutical marketing firm, where he worked on projects for Pfizer. Before becoming a Consultant, Dr. Werber served as Director of strategic business development at NotifyMD, a privately held e-health company. Dr. Werber served as Senior Biotech Analyst and Vice President at SG Cowen Securities. He began his career as a Research Associate and Business Analyst at the New England Medical Center. He is a member of the Board of Directors of the JCC in Manhattan and Finance for Israel Board of the Jewish National Fund. At Citi, Dr. Werber is ranked among the top analysts in the department. Over the past few years, he received high ranking in the 3rd party surveys including runner-up in the Institutional Investor Magazine survey 2012 and 2013, received recognition from Starmine for his coverage of the biotech sector and has been ranked among the top five analysts in the biotech sector by the ???Best on the Street Survey??? of the Wall Street Journal. He received a BS degree in Biology from Tufts University in 1994 and a combined MD and MBA degree in Healthcare Administration from Tufts University School of Medicine in 2000.

Amit Rakhit serves as the Chief Medical and Portfolio Management Officer of Ovid Therapeutics. Amit started at Ovid Therapeutics in April of 2016. Amit currently resides in the Greater New York City Area.

Jana Oberman serves as the Senior Director and Head of Regulatory Affairs of Ovid Therapeutics. Jana started at Ovid Therapeutics in February of 2018. Jana currently resides in the Greater New York City Area.

Ana Ward serves as the Senior Vice President & General Counsel |Chief Compliance Officer | Board Secretary | Head of IT of Ovid Therapeutics. Ana started at Ovid Therapeutics in September of 2017. Ana currently resides in the Greater New York City Area.

Dirk Haasner serves as the Senior Vice President Global Regulatory Affairs, CMC, and QA of Ovid Therapeutics. Dirk started at Ovid Therapeutics in December of 2015. Dirk currently resides in the Greater New York City Area.

Asif Paker serves as the Vice President Clinical Development of Ovid Therapeutics. Asif started at Ovid Therapeutics in April of 2017. Asif currently resides in the Greater Boston Area.

Jeannie Visootsak serves as the Vice President, Early Clinical Development, Rare Diseases of Ovid Therapeutics. Jeannie started at Ovid Therapeutics in August of 2016. Jeannie currently resides in the Greater New York City Area.